Naltrexone hydrochloride and bupropion hydrochloride, the active ingredients of Contrave, are combined in a prescription tablet for adults with obesity or overweight plus weight-related health problems. Contrave supports weight management alongside reduced-calorie eating and increased physical activity by influencing appetite and food-reward pathways in the brain.
Contrave supports weight management alongside reduced-calorie eating and increased physical activity by influencing appetite and food-reward pathways in the brain.
How much Contrave to use and how often depends on the purpose of use and is agreed with a doctor or pharmacist. It is used as part of a structured weight-management programme for adults with a body mass index (BMI) of at least 30 kg/m², or at least 27 kg/m² when weight-related conditions such as type 2 diabetes, high blood pressure, or abnormal blood lipids are present.
It is used as part of a structured weight-management programme for adults with a body mass index (BMI) of at least 30 kg/m², or at least 27 kg/m² when weight-related conditions such as type 2 diabetes, high blood pressure, or abnormal blood lipids are present. The European Medicines Agency describes the treatment as an adjunct to diet and exercise, rather than a replacement for them [1].
The medicine is intended for chronic weight management. Its role is to reduce appetite and help control cravings, which may make a calorie-controlled eating plan easier to maintain. Weight, waist measurement, blood pressure, mood, and treatment tolerability are usually reviewed during follow-up.
Contrave may be considered when lifestyle measures alone have not produced sufficient weight reduction and the patient meets the relevant BMI criteria. It is not intended for routine cosmetic weight loss in adults without obesity or weight-related medical risk.
The treatment programme includes:
Naltrexone is an opioid receptor antagonist. It blocks opioid receptors involved in food reward and may reduce the reinforcing effect that some people experience from eating highly palatable foods. Bupropion affects noradrenaline and dopamine signalling. These neurotransmitters participate in appetite regulation, motivation, and reward processing.
Together, the ingredients influence pathways linked with the hypothalamus and the mesolimbic reward circuit. The hypothalamus helps regulate hunger and energy balance. The mesolimbic pathway influences motivation and the perceived reward associated with food. The combined action may reduce hunger and help weaken repetitive food cravings. The pharmacology and dosing principles are described in the EMA product information [2].
Contrave is not for you if you:
This treatment may not be suitable if you have uncontrolled high blood pressure, seizures, an eating disorder, severe liver problems, or an allergy to its ingredients. It may also be unsuitable if you take opioids, another bupropion-containing medicine, or are stopping alcohol or sedatives suddenly. Do not use it for weight-loss treatment during pregnancy.
The most frequent adverse effects involve the digestive system and central nervous system. Nausea, constipation, headache, vomiting, dizziness, trouble sleeping, dry mouth, and diarrhoea have been reported with Contrave.
Nausea is often more noticeable during dose escalation. Smaller meals, slower eating, adequate fluid intake, and limiting greasy foods may help. Constipation may improve with fibre, fluids, and regular movement, provided these measures suit the person’s health.
| Common reaction | Practical management |
|---|---|
| Nausea or vomiting | Smaller meals, slower eating, and clinical review if persistent |
| Constipation or diarrhoea | Fluids, suitable dietary adjustments, and monitoring |
| Headache or dizziness | Rise slowly, avoid driving until clear-headed, and report severe symptoms |
| Insomnia or dry mouth | Earlier dosing when prescribed, regular sleep routine, and frequent sips of water |
Clinical trial adverse reactions and stopping rules are described in regulatory product information [3]. Many early symptoms become less troublesome as the body adjusts, though persistent or severe reactions require review.
A practical warning about constipation is easy to overlook. If abdominal pain, vomiting, and inability to pass stool occur together, this needs urgent medical assessment rather than self-treatment with repeated laxatives.
How much Contrave to use and how often depends on the purpose of use and is agreed with a doctor or pharmacist.
The formulation is not interchangeable with a separate bupropion product or a separate naltrexone product. The extended treatment plan depends on the combination and the patient’s response.
Contrave tablets are taken by mouth. The usual regimen is increased gradually during the early treatment period, and the exact amount and frequency are agreed with a doctor or pharmacist.
How much Contrave to use and how often depends on the purpose of use and is agreed with a doctor or pharmacist. The treatment is normally introduced gradually rather than started at the full maintenance schedule, which helps assess tolerability and limits early adverse effects.
The amount and frequency depend on the purpose of treatment and are agreed with a doctor or pharmacist. Tablets are swallowed whole with water.
The tablets use a modified-release design. Breaking or chewing one can alter how bupropion is released and may increase the risk of adverse effects, including seizures.
If a dose is missed, the safest approach is to skip it and take the next scheduled dose. Doubling up is not appropriate.
Weight-management medicines differ in their active ingredients, route, and main limitations. A suitable option depends on medical history, eating pattern, cardiovascular risk, diabetes status, and previous treatment response.
| Treatment category | Main action and route | Key clinical consideration |
|---|---|---|
| Contrave | Naltrexone plus bupropion tablets | Avoid with opioids, other bupropion products, seizure risk, and uncontrolled hypertension |
| GLP-1 receptor agonist therapy | Hormone-based appetite and glucose regulation, usually by injection | Gastrointestinal effects, injection use, and suitability for diabetes or obesity treatment |
| Orlistat-type therapy | Reduces absorption of dietary fat, taken orally | Oily stools, urgency, and the need to manage dietary fat intake |
Saxenda is a GLP-1 receptor agonist delivered by injection. Qsymia combines phentermine with topiramate and has neurological, cardiovascular, pregnancy, and misuse-related considerations. Xenical contains orlistat and acts in the gut rather than through central appetite pathways.
Belviq and Belviq XR, which contained lorcaserin, were withdrawn from the United States market after safety concerns. They are historical comparators rather than current choices. Comparative regulatory history for obesity medicines is summarised in FDA safety communications and clinical guidance [4].
Contrave may appeal to patients who prefer tablets and whose main difficulty involves cravings or reward-driven eating. Its drawbacks include nausea, insomnia, blood-pressure effects, seizure restrictions, and the opioid blockade.
Several avoidable errors reduce tolerability or create safety problems:
One small behavioural detail can matter: eating quickly may allow cravings to outpace the feeling of fullness. Slowing meals gives the appetite signal more time to register.
Clinicians generally assess Contrave as one part of a long-term weight-management plan. The medicine may help reduce appetite and food cravings, yet the result depends on continued dietary changes, movement, sleep, and follow-up.
A doctor will usually review:
A useful clinical expectation is gradual change rather than an immediate dramatic response. If appetite improves but weight does not change, the eating pattern, adherence, physical activity, fluid calories, and treatment suitability need review. If mood worsens or blood pressure rises, the safety assessment takes priority over weight loss.
A reduced-calorie eating plan and regular physical activity are part of the approved treatment approach described by the EMA in 2015. Meals built around protein, vegetables, fibre, and minimally processed carbohydrates may support satiety, while high-calorie drinks can work against the calorie deficit. The WHO’s healthy-diet guidance from 2020 also supports regular movement, adequate sleep, and limiting free sugars. Contrave does not remove the need to monitor portions or eating patterns. A registered dietitian can help adapt the plan to medical needs and preferences.
The EMA product information from 2015 specifies that the tablets should be swallowed whole. Crushing, chewing, or splitting can interfere with modified release and may increase exposure to bupropion too quickly. This can worsen nausea, dizziness, insomnia, or seizure risk. Use water to swallow the tablet rather than altering its form.
The EMA pharmacology information from 2015 describes Contrave as a repeated-dose treatment, not a medicine intended to provide a single short episode of appetite control. Its ingredients are taken on a regular schedule, with the regimen increased gradually during initiation. Appetite effects can vary across the day and between individuals. Missing doses or taking extra tablets does not create a safer or longer-lasting effect.
Contrave is intended for adults, and the EMA product information from 2015 does not establish routine use for children or adolescents. Weight-management treatment under 18 requires assessment of growth, puberty, eating behaviour, mental health, and family factors. The WHO paediatric obesity framework from 2022 emphasises structured lifestyle and clinical support for younger patients. Do not use adult Contrave treatment for a person under 18 without a specialist decision.
The EMA product information from 2015 reports dizziness and sleep-related adverse effects that can impair activities requiring alertness. Do not drive, cycle in traffic, or operate machinery until you know how Contrave affects concentration, balance, and vision. Alcohol may worsen dizziness or reduce judgement. Severe headache, blurred vision, confusion, or marked agitation requires prompt clinical attention.
The EMA treatment information from 2015 includes response assessment as part of continued use. A clinician may review adherence, diet, physical activity, sleep, fluid calories, other medicines, mood, and medical causes of weight change. NICE obesity guidance from 2025 supports regular review of treatment response and tolerability. Continuing indefinitely without a meaningful benefit or reassessing an unsuitable regimen is not appropriate.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
The first week brought nausea and a dry mouth, especially after a rushed breakfast. Those symptoms eased after the dose was increased more gradually. Cravings for evening snacks became easier to manage, although I still had to plan meals.
I noticed less interest in food, but constipation and poor sleep were frustrating. My blood pressure needed closer monitoring, and the treatment was stopped when the side effects outweighed the benefit.
The tablets helped with repeated grazing during work. Weight loss was slow rather than dramatic, and weekends remained difficult. Keeping alcohol low and eating regular meals made the biggest difference for me.
